April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
The Anti-Apoptotic Action of Curcumin and zVAD-fmk Provides a Potential Treatment for Ocular Coloboma in the lamb1 Zebrafish Model
Author Affiliations & Notes
  • M. Moosajee
    Clinical Neuroscience, Imperial College London, London, United Kingdom
    Western Eye Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
  • C. Y. Gregory-Evans
    Clinical Neuroscience, Imperial College London, London, United Kingdom
  • K. Gregory-Evans
    Clinical Neuroscience, Imperial College London, London, United Kingdom
    Western Eye Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
  • Footnotes
    Commercial Relationships  M. Moosajee, None; C.Y. Gregory-Evans, None; K. Gregory-Evans, None.
  • Footnotes
    Support  St. Mary’s Development Trust Award
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4810. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Moosajee, C. Y. Gregory-Evans, K. Gregory-Evans; The Anti-Apoptotic Action of Curcumin and zVAD-fmk Provides a Potential Treatment for Ocular Coloboma in the lamb1 Zebrafish Model. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4810.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Ocular coloboma arises from incomplete fusion of the optic fissure between 5-7 weeks post conception in humans and 36-48 hours post fertilisation (hpf) in zebrafish. The aetiology of this congenital eye anomaly shows extensive genetic heterogeneity, and there is no effective treatment available. Apoptosis plays a transient role in normal optic fissure morphogenesis, however, deleterious levels have been detected at the site of the unfused optic fissure in a number of animal models of ocular coloboma, including the lamb1-/- zebrafish. This study aims to identify whether drugs targeting apoptosis can provide a safe, effective and mutation-independent treatment for ocular coloboma, and improve understanding of the cellular mechanisms involved in optic fissure morphogenesis.

Methods: : Mutant lamb1-/- embryos were treated with 5 µM curcumin (diferuloylmethane, a caspase-3 inhibitor, derived from Curcuma longa), 300 µM zVAD-fmk (fluoromethylketone molecule, a pan-caspase inhibitor) and 300 µM zFA-fmk (negative control, cathepsin B inhibitor) from 10 hpf; ocular morphology was examined by light microscopy at 48 hpf and day 6. The lamb1-/- mutation causes lethality by day 5; survival times were determined for treated and untreated larvae (n=50 per group). Apoptosis at the site of the optic fissure was detected by TUNEL assay.

Results: : Curcumin and zVAD-fmk-treated lamb1-/- mutants displayed a significantly milder coloboma phenotype associated with negligible TUNEL-positive staining at the site of the persistent optic fissure, compared to zFA-fmk and untreated embryos at 48 hpf and day 6. Mean survival of lamb1-/- mutants treated with both drugs resulted in a 1.4 fold increase in survival (average 7.1 days, p>0.0001 using the Mann-Whitney Test).

Conclusions: : Both anti-apoptotic agents greatly reduced the size of the colobomatous defect by minimising cell death. This suggests optic fissure remodelling requires apoptosis, but is not wholly dependent on this mechanism. Supplemental curcumin may provide a safe prenatal treatment which limits the severity of ocular coloboma and has applications for use in other ocular developmental anomalies displaying pathological levels of apoptosis.

Keywords: development • apoptosis/cell death • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×